Oncology

#Antibiotics #Autoimmune disease #Genetics / genomics #Oncology #Painkillers #T cell engagers

This week in drug discovery (18-22 November) 

News round-up for 18-22 November by DDW Senior Digital Content Editor Diana Spencer. This week’s most exciting news stories all represent innovative solutions to the treatment of disease, proving that ‘thinking outside the box’ can by the key to success in drug discovery. The top stories:… Read More

#News

Genomics
#Gene sequencing #Genetics / genomics #Oncology #The Institute of Cancer Research

Whole-genome sequencing reveals new potential cancer-driving genes

Researchers have identified 330 potential cancer-driving genes, 74 of which are newly associated with cancer. The findings highlight the potential to develop new, more targeted treatment options and provide hope that existing cancer treatments, such as PARP inhibitors, could be extended to thousands more patients. Read More

#Cancer Research #Editor's Choice #News

Immunotherapy
#Cancer Research Institute #Immunotherapy #Interview #Oncology

Why immunotherapy still holds so much potential

Dr Jill O’Donnell Tormey, CEO and Director of Scientific Affairs at the Cancer Research Institute, US, discusses the future of cancer research with DDW's Megan Thomas. Innovation & opportunity Reflecting on innovation and opportunity in global cancer research, Dr Jill O’Donnell-Tormey recognises modalities like cell therapies, bispecifics, antibody drug conjugates… Read More

#Cancer Research #Exclusive Content

CAR-T therapy
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology #Webinar

Characterise CAR-T cells: Address ‘on target, off tumour’ effects

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. But how can you enhance the characterisation and expansion of CAR-T cells and address ‘on target, off tumour’ effects? Register now for this exclusive… Read More

Webinar date:
Supported by Sartorius
#News

#Cancer immunotherapy #Events #Immunotherapy #Oncology

New DDW Highlights podcast: 18 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the Society for Immunotherapy of Cancer (SITC) 2024 taking place in Houston… Read More

#News

#Cancer immunotherapy #Events #Immunotherapy #Oncology

This week in drug discovery (11-15 November) 

News round-up for 11-15 November by DDW Senior Digital Content Editor Diana Spencer. With the Society for Immunotherapy of Cancer (SITC) 2024 taking place in Houston recently, there have been a number of recent announcements regarding the clinical advancement of immunocytokines, METTL3 inhibitors, cancer vaccines, CAR-T therapies and immune… Read More

#News

Leukaemia
#Acute Myeloid Leukaemia #Blood cancer #Oncology #The Institute of Cancer Research

New target for acute myeloid leukaemia discovered

Researchers have identified a key weakness in acute myeloid leukaemia (AML), offering a promising new strategy to delay the progression of this aggressive blood cancer. The discovery focuses on disrupting the function of the nucleosome-remodelling factor (NURF) complex, which cancer cells, including leukaemia cells, rely on… Read More

#Cancer Research #Editor's Choice #News

#Cell therapy #Financing #Oncology #Phase I trial #Vittoria Biotherapeutics

Vittoria raises $25 million to accelerate T cell therapies

Immunotherapy company Vittoria Biotherapeutics has successfully completed a $25 million private financing round. This funding is a $10 million extension to its previous $15 million financing secured in November 2023. The latest round was led by Valley Forge Investment Corporation, with new investments from the Global BioAccess Fund and Hatch… Read More

#Business & Investment #News

Prostate cancer cells
#Bladder cancer #Immunotherapy #Oncology #Prostate cancer #UCLA

Immunotherapy with chemotherapy effective for rare cancers

New research has found that combining immunotherapy with chemotherapy is safe and effective for people with advanced small cell cancers in the bladder and prostate. A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with… Read More

#Cancer Research #Editor's Choice #News

CAR-T therapy for leukaemia
#Autolus #CAR-T #Cell therapy #FDA #Immunotherapy #Leukaemia #Oncology

First FDA approval for new CAR-T therapy

The US Food and Drug Administration (FDA) has approved Autolus’ obecabtagene autoleucel (Aucatzyl), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). The efficacy of obecabtagene autoleucel was evaluated in FELIX, an open-label, multicentre, single-arm trial that enrolled adults… Read More

#News #Regulatory #Trending News

Cytokines
#Cancer research #Cell therapy #Cytokines #Oncology

Harnessing nature’s ‘cues’ in the treatment of cancer

Megan Thomas spoke with Dan Passeri, CEO of Cue Biopharma, about why the company’s pipeline of cytokine-based drugs are so promising for cancer treatment. MT: Why is this a promising area of oncology research? DP: Cytokines, such as interleukin 2 (IL-2), are potent immunostimulant molecules and well-characterised activators of T… Read More

#Cancer Research #Exclusive Content

Cytokines
#Cytokines #Events #Immunotherapy #Oncology #Solid tumours #SOTIO

PD-1-targeting immunocytokine reinvigorates T cells

New data supporting SOT201, a PD-1-targeting immunocytokine, in advanced solid tumours was presented at the 2024 Society for Immunotherapy of Cancer (SITC) Meeting in Houston, TX, US. SOT201 is a PD-1-targeted and cis-acting attenuated IL-15 agonist designed to preferentially activate PD-1+CD8+ T cells, inducing superior anti-tumour… Read More

#Cancer Research #News

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #High throughput screening #Live cell analysis #Oncology #Webinar

Webinar: Enhance the characterisation of CAR-T cells

The development of gene-modified cell therapies, particularly CAR-T cells, has transformed cancer treatment by offering personalised and potentially curative options. But how can you enhance the characterisation and expansion of CAR-T cells and address ‘on target, off tumour’ effects? Register now for this exclusive… Read More

Webinar date:
Supported by Sartorius
#News

#Cancer drug targets #Genetics / genomics #Oncology #Precision medicine #Synthetic lethality

The promise of synthetic lethality in precision oncology

Kathryn L Chapman, Head of Discovery Biology & Jürgen Moll CSO at Tesselate Bio, explore alternative approaches to synthetic lethality to target cancer cells that use alternative lengthening of telomersin. Synthetic lethality and targeted drugs are a clinically established approach Synthetic lethality (SL) is an established, clinical and commercial approach… Read More

#Cancer Research #Exclusive Content

Bladder
#Bladder cancer #Johnson & Johnson #MHRA #Oncology #Phase III trial

MHRA approves erdafitinib for some urothelial carcinomas

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Balversa (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC). Specifically, the indication covers patients harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, who have previously received… Read More

#News #Regulatory

Circular DNA concept
#Cancer Grand Challenges #DNA #Oncology #The Francis Crick Institute #University College London

Targeting circular DNA could treat the most aggressive cancers

Scientists have discovered a way to target elusive circular fragments of DNA that drive the survival of some of the most aggressive cancers, paving the way for future treatments. In three papers published today in Nature, scientists from the Cancer Grand Challenges team eDyNAmiC and their… Read More

#Cancer Research #News #Trending News